BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 28416487)

  • 1. Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging.
    Sans M; Gharpure K; Tibshirani R; Zhang J; Liang L; Liu J; Young JH; Dood RL; Sood AK; Eberlin LS
    Cancer Res; 2017 Jun; 77(11):2903-2913. PubMed ID: 28416487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 3. Imaging in gynecological disease (12): clinical and ultrasound features of invasive and non-invasive malignant serous ovarian tumors.
    Moro F; Baima Poma C; Zannoni GF; Vidal Urbinati A; Pasciuto T; Ludovisi M; Moruzzi MC; Carinelli S; Franchi D; Scambia G; Testa AC
    Ultrasound Obstet Gynecol; 2017 Dec; 50(6):788-799. PubMed ID: 28101917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extrauterine Pelvic Serous Carcinomas: Current Update on Pathology and Cross-sectional Imaging Findings.
    Katabathina VS; Amanullah FS; Menias CO; Chen MM; Valente PT; Chintapalli KN; Prasad SR
    Radiographics; 2016; 36(3):918-32. PubMed ID: 27163599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical characteristics of borderline ovarian tumors and stage I epithelial ovarian cancer: an analysis of 143 cases].
    Zhao Y; Wang Y; Shen Dh; Song Rn; Xu Q; Li Y; Cui H; Tang J; Wei Lh
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 43(1):123-8. PubMed ID: 21321635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and prognostic significance of epithelial-mesenchymal transition-related markers and phenotype in serous ovarian cancer.
    Song IH; Kim KR; Lim S; Kim SH; Sung CO
    Pathol Res Pract; 2018 Oct; 214(10):1564-1571. PubMed ID: 30082157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The "Far Left" of the Morphologic Spectrum of Ovarian High-grade Serous Carcinoma: Case Report of a Purely Noninvasive High-grade Serous Carcinoma Mimicking an Ovarian Serous Borderline Tumor.
    Katsakhyan L; Baraban EG; Dumoff KL; Burger RA; Parikh R; Cooper K
    Int J Gynecol Pathol; 2021 Mar; 40(2):175-179. PubMed ID: 32168063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep Metabolomics of a High-Grade Serous Ovarian Cancer Triple-Knockout Mouse Model.
    Huang D; Gaul DA; Nan H; Kim J; Fernández FM
    J Proteome Res; 2019 Aug; 18(8):3184-3194. PubMed ID: 31290664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
    Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
    APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance imaging for distinguishing ovarian clear cell carcinoma from high-grade serous carcinoma.
    Ma FH; Qiang JW; Zhang GF; Li HM; Cai SQ; Rao YM
    J Ovarian Res; 2016 Jul; 9(1):40. PubMed ID: 27377917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum.
    Ohsuga T; Yamaguchi K; Kido A; Murakami R; Abiko K; Hamanishi J; Kondoh E; Baba T; Konishi I; Matsumura N
    BMC Cancer; 2017 Aug; 17(1):580. PubMed ID: 28851311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
    Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
    Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
    [No Abstract]   [Full Text] [Related]  

  • 14. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
    Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomics of High-Grade Serous Ovarian Cancer Models Identifies Cancer-Associated Fibroblast Markers Associated with Clinical Outcomes.
    Govindarajan M; Ignatchenko V; Ailles L; Kislinger T
    Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
    Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
    Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The expression of IMP3 in 366 cases with ovarian carcinoma of high grade serous, endometrioid and clear cell subtypes.
    Lu L; Wang S; Zhu Q; Qu Y; Gu W; Ning Y; Chen X; Wang Y
    Pathol Res Pract; 2018 Aug; 214(8):1087-1094. PubMed ID: 29866423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HNF-1β in ovarian carcinomas with serous and clear cell change.
    DeLair D; Han G; Irving JA; Leung S; Ewanowich CA; Longacre TA; Gilks CB; Soslow RA
    Int J Gynecol Pathol; 2013 Nov; 32(6):541-6. PubMed ID: 24071869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer.
    Klinkebiel D; Zhang W; Akers SN; Odunsi K; Karpf AR
    Mol Cancer Res; 2016 Sep; 14(9):787-94. PubMed ID: 27259716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: A nationwide study.
    Hannibal CG; Frederiksen K; Vang R; Kurman RJ; Kjaer SK
    Int J Cancer; 2020 Aug; 147(4):990-995. PubMed ID: 31930502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.